VentriPoint Diagnostics (CVE:VPT) Trading Up 16.7% – Still a Buy?

VentriPoint Diagnostics Ltd. (CVE:VPT)’s stock price shot up 16.7% during mid-day trading on Wednesday . The stock traded as high as C$0.16 and last traded at C$0.14. 786,338 shares were traded during mid-day trading, an increase of 371% from the average session volume of 167,095 shares. The stock had previously closed at C$0.12.

VentriPoint Diagnostics Stock Up 16.7%

The stock has a market cap of C$23.48 million, a P/E ratio of -4.67 and a beta of -0.41. The firm has a 50 day simple moving average of C$0.10 and a 200-day simple moving average of C$0.11. The company has a quick ratio of 6.67, a current ratio of 0.28 and a debt-to-equity ratio of -58.56.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.